Home >> Tag Archives: Insight Genetics—

Tag Archives: Insight Genetics—

Insight Genetics offers TNBC test

February 2019—Insight Genetics launched its proprietary Insight TNBCtype, a test for categorizing triple-negative breast cancer tumors into distinct molecular subtypes through its wholly owned CLIA- and CAP-accredited laboratory, Insight Molecular Labs.

Insight Genetics and VICC partnership, 5/14

Marketplace Archives

May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient.

Insight awarded NCI contracts for lung cancer research, 2/13:111

Marketplace Archives

Insight Genetics has received from the National Cancer Institute two small business innovation research contracts to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients.

Conferences/Events
and Webinars for Pathologists and Laboratory Professionals
Easily find continuing education offerings that meet your needs. Search by date, location, event type, and specialty.

Featured Event:
University of Miami Annual Pathology Conference
January 21–25, 2019
Miami Beach, FL
This popular course will provide the participant with the most recent and practical advances in Anatomic and Clinical Pathology with emphasis on the areas of head and neck pathology, cytopathology, thoracic pathology, hematopathology, immunohistochemistry, molecular pathology, clinical test utilization and new billing and management trends in healthcare.
[Event Details]

“So I guess there really is such a thing as improving upon perfection.”
— Dwayne Breining, MD, on a hypercritical values policy that strengthened an already effective critical value notification process at Northwell Health (“Labs add safety net to critical values procedure”)

“We haven't seen anything like that for the past 10 years, so this is brand new.”
— Hung Luu, PharmD, MD, on the FDA recognizing there is a need for greater participation by vendors in assigning LOINC codes to their tests and the FDA's recent guidance (“FDA nudges standards adoption in electronic reporting”)

PD-L1 Testing in Metastatic Triple Negative Breast Cancer: Challenging Cases To Help Update Your Practice

Tuesday, March 26, 2019, 1 PM–2 PM ET
Webinar presenters Ashley Cimino-Mathews, MD, Associate Professor of Pathology and Oncology Director of the Breast Pathology Program, The Johns Hopkins Hospital, Baltimore, Maryland, and Leisha A. Emens, MD, PhD, UPMC Hillman Cancer Center/Magee Women's Hospital Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, Pittsburgh, Pennsylvania, will discuss the challenges in PD-L1 testing in TNBC today.
Register Now ...

A LEAN Approach to Pap Processing: Spinning into the Future with BD

Tuesday, April 2, 2019, 1PM–2PM ET
Webinar presenter Melissa Randolph, BS, SCT (ASCP), Cytopathology Supervisor, Indiana University Health, will detail the transformation of LEAN processes within an academic facility that have allowed us to virtually eradicate the Unsatisfactory rate and reduce the ASC-US rate, all while maintaining LEAN staffing and significant walkaway advantages.
Register Now ...

The Evolving Role of BRCA Testing in Ovarian Cancer

Wednesday, April 10, 2019, 1:30 PM–2:30 PM ET
Webinar presenters Dana Chase, MD, FACOG, Assistant Professor, Division of Gynecologic Oncology University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, Gynecologic Oncologist, Arizona Oncology, and John Longshore, PhD, FACMG, Director, Molecular Pathology, Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, will discuss the link between molecular profiles and disease pathogenesis in ovarian cancer. Register Now ...

Why DMTs are a critical ingredient in the delivery of value-based care

Webinar presenters Michael Laposata, MD, PhD, University of Texas Medical Branch at Galveston Pathology, Chairman, and Bruce Friedman, MD, University of Michigan, Pathology, Emeritus Professor, Informatics, discuss the barriers that exist for the rapid and significant growth of diagnostic management teams to reduce medical error and optimize laboratory test use, overcoming barriers to DMT implementation, addressing connectivity between experts and doctors, and identifying ways to overcome DMT resistance from your peers. This on-demand webinar was hosted before a live audience at DMT Conference Galveston Island Convention Center, Galveston, Texas, on March 5, 2019.
Watch Now

IGHV clinical utility in CLL and preferred testing practices

Webinar presenter Curtis A. Hanson, MD, Professor of Laboratory Medicine and Pathology Mayo Clinic College of Medicine, Rochester, Minnesota, reviews the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. He also provides best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients. This on-demand webinar originally broadcast on February 28, 2019.
Watch Now

MALDI-TOF for the clinical identification of mycobacteria

Webinar presenter Omai Garner, PhD, D(ABMM), Assistant Clinical Professor, Section Chief, Clinical Microbiology, Director, Point of Care Testing, UCLA Department of Pathology and Laboratory Medicine, discusses the implementation and clinical use of MALDI-TOF MS for mycobacterial identification. It covers in detail the clinical data surrounding organism identification. It also explores the lab protocol (workflow impact) and turnaround time improvements (clinical impact) for this new technology. This on-demand webinar originally broadcast on December 13, 2018.
Watch Now

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Sam Caughron, MD, President & Managing Partner, Director of Molecular Lab, MAWD Pathology Group, discusses discusses Pathologists play a crucial role in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on November 29, 2018. Watch Now

Resectability in stage III NSCLC:
Case-based considerations for clinical decision making

Webinar presenters Michael Walker, MD, System Chief, Thoracic Surgery, Medical Director, Cancer Program, Main Line Health, and Tracey Evans, MD, Director, Thoracic Oncology Research, Co-Director, Thoracic Oncology Program, Associate Program Director, Hematology/Medical Oncology Fellowship Program, Lankenau Cancer Center, discuss AJCC staging guidelines for lung cancer, specifically Stage III disease. This on-demand webinar originally broadcast on November 14, 2018.
Watch Now

Homologous recombination deficiency and BRCA testing in ovarian and breast cancer

Webinar presenters Dana Chase, MD, Michelle Shiller, DO, and Tabetha Sundin, PhD discuss the role of BRCA1/2 mutations in homologous recombination deficiency and carcinogenesis, homologous recombination deficiency as a marker of treatment sensitivity, the testing process for homologous recombination deficiency and BRCA mutations, and the role of BRCA testing in ovarian and breast cancer. This on-demand webinar originally broadcast on October 23, 2018.
Watch Now

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Tabetha Sundin, PhD, HCLD, MB, discusses the crucial role pathologists play in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on October 3, 2018.
Watch Now